Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination



Rating:

Share or cite this content

Citations should be made in the following way:
G. B. Migliori (Tradate, Italy). MDR-TB management: what is new?. School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination

Member's Comments

No comment yet.

Related content which might interest you: TB/HIV management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 MDR-TB guidelines: what is new on clinical management Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management Year: 2020 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 TB and MDR-TB: what is new in 2012? Source: Breathe 2012; 9: 100-111 Year: 2012 Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures? Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 MDR-/XDR-TB: what are the unresolved problems in the clinical management? Source: Annual Congress 2012 - PG7 TB and MDR-/XDR-TB: what is new in diagnosis, treatment and follow-up (TB PAN-NET) Year: 2012 TB "cross-border" - a new challenge in tuberculosis management Source: Virtual Congress 2020 – Tuberculosis and society Year: 2020 The global response to rifampicin-resistant tuberculosis: Current situation and recent trends Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 MDR-TB: Early screening or future screaming Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016 New perspectives in MDR-TB management Source: International Congress 2016 – China Session II Year: 2016 Two major problems in TB patients today: MDR and the abandoned therapy Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017 Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives Source: Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019 Year: 2019 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Failure predictors when treating MDR-TB Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Current approaches to formulate evidence-based recommendations: a case study of WHO drug-resistant tuberculosis treatment guidance Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018